DUBLIN--(BUSINESS WIRE)--The "Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.
The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022
The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.
Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan.
The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.
Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and GlaxoSmithKline
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Market Overview
Chapter 5 Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
- Gilead Sciences
- Eli Lilly
For more information about this report visit https://www.researchandmarkets.com/research/gxfj7v/angina_pectoris?w=4